German Ophthalmological Society (DOG) Honors Uta Gehlsen, PhD, with Prestigious Scientific Award for Her Research on the Use of Semifluorinated Alkanes in Dry Eye Treatment
The German Ophthalmological Society (DOG) presented Uta Gehlsen, PhD, Ocular Surface Group, Department of Ophthalmology, University of Cologne, with the “Dry Eye and Blepharitis/MGD” Award for her research related to the use of a semifluorinated alkane (SFA F4H5) as a novel carrier for cyclosporine A for the topical treatment of dry eye disease (DED).1
The DOG Awards recognize scientific and academic excellence, the advancement of young researchers, interdisciplinary and internationality in the field of ophthalmology. Sponsored by Optima Pharmazeutische GmbH, the award was presented on Saturday, September 30, 2017 during the 115th DOG Congress in Berlin.
Dr. Gehlsen’s research, which was published in Graefe’s Archive for Clinical and Experimental Ophthalmology in January 2017, found that a cyclosporine A formulation using F4H5 as its vehicle (CyclASol®, Novaliq) was equally effective but had a significantly faster therapeutic response in reducing the signs of DED compared to a commercially available treatment in an experimental mouse model.
Topical cyclosporine is a well-established medication used to treat signs of DED. It has anti-inflammatory effects and prevents T-cell activation. Clinical studies have shown that it is effective in reducing corneal staining and/or increasing tear production. Cyclosporine is also a highly lipophilic substance typically formulated as an emulsion which often causes adverse side effects with burning and stinging sensations due to the involved surfactants. The premise of the study was to learn whether a new SFA drug delivery system may improve efficacy or tolerability of cyclosporine.
“It is an honor to have been recognized by the DOG for our work in the area of SFA drug delivery technology and dry eye disease,” said Dr. Gehlsen. “Using the desiccating-stress dry-eye mouse model enables us to perform highly standardized pre-clinical in-vivo testing of topical therapies for inflammatory dry eye disease. Our experimental studies with several cyclosporine formulations hereby demonstrated a significantly faster and equally effective topical treatment effect for CyclASol® compared to other commercially available products. I am very pleased that our experimental results for CyclASol® have now been confirmed in the CYS-002 multicenter US clinical trial and hopefully will be soon available to treat patients suffering from dry eye disease.”
In this pre-clinical study, 0.05% cyclosporine dissolved in the F4H5 (CyclASol®) was found to be highly effective in reducing corneal staining and increasing tear production. Compared to the commercially available therapy comparator group, CyclASol® demonstrated at least a comparable therapeutic effect, but with a significantly faster response. Notably, early therapy with CyclASol® protected mice from developing dry eye, whereas all other study groups showed a significant increase of staining compared to baseline. CyclASol® also was the only studied treatment that demonstrated a prophylactic effect.
“On behalf of Novaliq, I congratulate Dr. Gehlsen for being presented with this award by the prestigious German Ophthalmological Society,” said Christian Roesky, PhD, managing director and CEO, Novaliq GmbH. “Through their research, we are better able to understand the many benefits of the SFA vehicle when added to traditionally insoluble or unstable drugs such as cyclosporine. Equipped with this knowledge, Novaliq has developed a very exciting and robust dry eye pipeline that has the potential to address significant unmet medical needs.”
About CyclASol ® – CyclASol® is a clear, preservative-free ophthalmic solution of cyclosporine A formulated using Novaliq’s proprietary EyeSol® drug delivery technology.
About Novaliq – Novaliq GmbH, founded in 2007, is a Heidelberg based specialty pharmaceutical company focused on ophthalmology. Its mission is to transform poorly soluble drugs into effective ocular therapeutics for both the front and the back of the eye. Novaliq’s proprietary EyeSol ® technology enhances the topical bio-availability, stability and safety of traditionally insoluble or unstable drugs improving the delivery, efficacy and convenience of treatments for ocular surface diseases including dry eye through preservative free and multi dose formulations. Novaliq has developed a tiered and long-term sustainable dry eye family of truly differentiated products that addresses the different needs of dry eye patients. Novaliq’s most advanced product is NovaTears® with CE-approval marketed under the brand name EvoTears® in Europe. CyclASol ® a second-generation prescription drug is currently in preparation for a pivotal trial. More on www.novaliq.com.
About German Ophthalmological Society (DOG)—The DOG is the medical scientific association of ophthalmology in Germany and besides the oldest ophthalmological association in the world. It unites more than 7,000 ophthalmologists in hospitals, medical and research units. One of its main scopes is to advance scientific progress in ophthalmology and to transfer acknowledged findings into the daily routine in clinics and physicians’ practices.
1. Gehlsen U, Braun T, Notara M, Krösser S, Steven P; A semifluorinated alkane (F4H5) as novel carrier for cyclosporine A: a promising therapeutic and prophylactic option for topical treatment of dry eye; Graefes Arch Clin Exp Ophthalmol 2017; 255(4): 767-775
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
LIAF: Experts at the European Parlament - E-Cigarettes Are a Potential Game Changer for European Health20.3.2018 21:27 | Tiedote
The following is a statement from LIAF – Lega Italiana Anti Fumo: The panel discussion at the EU Parliament recognises the potential benefits of electronic cigarettes and for European countries to treat these products as regular consumer products to ensure equal access for all Europeans. Following a debate in which leading scientific experts presented the state-of-the-art evidence around e-cigarettes, it became clear that public health is increasingly moving on from an approach that solely advocates ‘quit-or-die’ to a harm reduction strategy. “I’m glad to have brought the Parliament attention to this important issue for public health. Today we have listened to the results of scientific studies and researches from a high-level expert’s roundtable, which have illustrated to us the advantages of electronic cigarettes and the potential public health benefits that these products pose when compared to the conventional cigarettes. As decision-makers, we need to take into considerations these
Morinaga Milk's New Probiotic Strain, Bifidobacterium breve A1, May Prevent Onset of Alzheimer's Disease20.3.2018 21:00 | Tiedote
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, today announced the results of a new study investigating the preventive effects of its new probiotic strain Bifidobacterium breve A1 on a model of Alzheimer’s disease. Researchers found that B. breve A1 improved spatial recognition capability, as well as learning and memory capabilities, in cognitively deficient mice, indicating it could play an important role in preventing the onset of Alzheimer’s Disease in humans.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180320005052/en/ (Fig. 1) Effects of B. Breve A1 in improving spatial recognition, learning and memory capabilities (Graphic: Business Wire) The number of patients affected by dementia is increasing worldwide. One report estimates there were 46.8 million people worldwide living with dementia in 2015 and projects this number will reach 131.5 million by 2050.2 Alzheimer’s disease
Dubai Breaks Ground on World’s Biggest CSP Project20.3.2018 19:10 | Tiedote
HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, broke ground on the 4th phase of the Mohammed bin Rashid Al Maktoum Solar Park. This is the biggest Concentrated Solar Power (CSP) investment project in the world, based on the Independent Power Producer (IPP) model, and will generate 700MW on a single site. It will have the world’s tallest solar tower at 260 metres, and the largest thermal energy storage capacity in the world. It will provide clean energy to 270,000 residences, reducing 1.4 million tonnes of carbon emissions annually. The project will use two technologies: a 600MW parabolic basin complex and a 100MW solar tower, over 43 square kilometres. This project, with AED14.2 billion in investments, achieved the lowest Levelised Cost of Electricity (LCOE) of USD 7.3 cents per kW/h. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180320006214/en/ Dubai breaks groun
Edgecore Networks Introduces 400G Open Networking20.3.2018 19:00 | Tiedote
OCP Summit – Edgecore Networks, the leader in open networking, today announced its contribution to the Open Compute Project (OCP) of the design of a 400 Gigabit Ethernet (400G) data center switch, the industry’s first 400G open design, that will enable public and private network operators to increase dramatically the capacity of their infrastructures. “Four years ago, Edgecore contributed the industry’s first OCP-ACCEPTED™ network product, a 10G top-of-rack switch,” said George Tchaparian, CEO, Edgecore Networks. “Since then, we have contributed over 15 network product designs as open networking technology and deployments grew to include 25G/100G data center fabrics, deep-buffer data center interconnect switches, service provider access infrastructures, open modular chassis, and campus/branch/wireless networks. Now, Edgecore is introducing the industry’s first 400G open network switch, enabling network operators to respond to growing demands for network capacity, and increasing the ban
Technics Organizes World's First Full Turntable Orchestra20.3.2018 17:48 | Tiedote
On March 20, 2018, the "Record Day," Panasonic Corporation released the video of the world's first full orchestra performance featuring Technics "turntables (analog record players)" as the only instruments, under the Technics brand's theme, "Rediscover Music." This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180320006023/en/ World's First Full Turntable Orchestra organized by Technics (Photo: Business Wire) Videos: - THE PHILHARMONIC TURNTABLE ORCHESTRA https://youtu.be/JGWuyMKT8wU - BEHIND THE BEATS : THE PHILHARMONIC TURNTABLE ORCHESTRA https://youtu.be/J2KK3vqJqog "The Philharmonic Turntable Orchestra" special website Thirty renowned DJs from around the world, including DJ Rena, the reigning Japanese world champion (youngest ever world champion in history), who took the "DMC World Championship" title in 2017 at just 12 years old*, came together to create the world's first "turntable orchestra." Using the Technics' iconic tu
Bentley Systems' Year in Infrastructure 2018 Conference and Awards Gala to be Held in London, Oct. 15-1820.3.2018 17:30 | Tiedote
Bentley Systems, Incorporated, a leading global provider of comprehensive software solutions for advancing infrastructure, today announced that the Year in Infrastructure 2018 Conference will be held Oct. 15 through 18 in London at the Hilton London Metropole. Presented by Bentley Institute, the conference is a global gathering of leading industry executives and prominent thought leaders in the design, construction, and operations of the world’s infrastructure. The theme of this year’s conference is Going Digital: Advancements in Infrastructure. The conference features nearly 70 speakers and more than 50 informative sessions, including keynotes by leading industry experts, interactive workshops, forums, panel discussions, and product demonstrations. Attendees can visit the Technology Pavilion, which features exhibits and presentations from Bentley Systems and its strategic partners Microsoft, Siemens, Topcon, and Bureau Veritas. On the first day of the conference, Bentley Institute wil
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme